By Patricia Weiss

SAN SEBASTIAN, Spain (Reuters) -Bayer has started the third phase of human testing of an experimental stem cell therapy for Parkinson’s disease, with future results potentially underpinning a request for regulatory approval, the company said on Monday.

Despite still being years from market launch, Bayer, which spent about $250 million on a new facility for cell therapies in California in 2023, said it is already working on a manufacturing network for the cell-replacement therapy.

The cell and gene therapy push has been seen by investors as an uncertain longer-term attempt to revive its drug development pipeline while it seeks to reduce financial debt and fight litigation that could cost it billions of dollars.

COMPETING CELL THERAPIES FOR PARKINSON’S DISEASE

Over the

See Full Page